Stakeholders testified before a House of Representatives subcommittee about the impact of the rising costs of insulin, while the FDA announced it will hold a public hearing May 13 about its plan to transition follow-on insulins to a regulatory pathway for biosimilars.
As a House of Representatives subcommittee met Tuesday to hear from stakeholders affected by the rising costs of insulin, the FDA announced it will hold a public hearing May 13 about its plan to transition follow-on insulins to a regulatory pathway for biosimilars.
According to the FDA, insulins will be regulated as biologics in 2020; currently, insulins and a number of other therapies, like hormones, are regulated as drugs and follow-on products. Once insulins are regulated as biologics under section 7002(e) of the Biologics Price Competition and Innovation Act, it will be possible for developers to seek interchangeable designations for their subsequent-entry versions, which will allow for pharmacy-level substitution and the potential for cost savings.
Those cost savings are desperately needed by patients with diabetes, where 1 in 4 patients are skipping doses or rationing their medication due to price, witnesses told the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce.
“Regulatory systems and patent extensions restrict the introduction of more generics and biosimilars,” said Alvin C. Powers, MD, director of the Vanderbilt Diabetes Center and chief of the Vanderbilt Division of Diabetes, Endocrinology, and Metabolism, and testifying for the Endocrine Society,
The 1 in 4 statistic came from Kasia J. Lipska, MD, from the Yale-New Haven Hospital Center for Outcomes Research and Evaluation at the Yale University School of Medicine. In a survey of 199 patients at the Yale Diabetes Center, rationing affected patients across all different prescription coverage plans as well as across most demographic factors, although those with incomes below $100,000 were more likely to ration insulin, she said.
Holding up a vial of Eli Lilly and Company’s insulin lispro (Humalog), Lipska noted that it cost $21 in 1996 but now costs more than $270. “Eli Lilly has made a big deal about its authorized generic,” she said, referring to an announcement last month that the company would cut the list prices 50% for its own generic of the brand version. But that price—$137.50—is still much higher than $21, she pointed out.
“I think we have a moral obligation to address this problem,” she said.
The fact that one-fourth of patients skip insulin doses was echoed by William T. Cefalu, MD, the chief scientific, medical and mission officer for the American Diabetes Association (ADA), who noted that rationing can lead to fatal or near-fatal complications.
Similar to other witnesses, Cefalu discussed the lack of transparency in the pharmacy supply chain, including pharmacy benefit managers (PBMs).
“If biosimilars were more like generics, we would have a lower price,” said Cefalu, who testified that the regulatory framework for development and approval of follow-on insulins is burdensome for manufacturers, and that prices for follow-on insulins are not likely to be reduced unless there are several biosimilars that can be substituted for the brand name analog insulin.
The FDA said Tuesday it expects that approval of the newer insulins will create competition and will provide affordable treatment options. It said it wants input at the public meeting from stakeholders and patients as it prepares for the submission and review of applications for biosimilar and interchangeable insulin products.
The hearing also touched on the role of ending rebates in Medicare Part D as one possible way to lower what patients pay at the pharmacy counter, as proposed by HHS. Energy and Commerce Committee Chairman Frank Pallone Jr, D-New Jersey, said he had concerns about it, but Christel Marchand Aprigliano, MS, chief executive officer of the Diabetes Patient Advocacy Coalition, said her organization supports the idea.
Aaron J. Kowalski, PhD, the chief mission officer of the JDRF, said his organization believes that competition drives innovation and affordability. “We aren’t saying that insulin companies shouldn’t be profitable,” he said. "They're selling insulin abroad at much lower price. The question is how can we make that happen in the United States of America and make sure insulins are affordable?"
“Having generics or biosimilars come to the market is another way of having affordability,” he added.
The hearing, one of many related to insulin or drug costs taking place on Capitol Hill recently, will continue next week when the subcommittee hears from PBM representatives.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.